HK1109155A1 - Pyrrolidine inhibitors of iap - Google Patents

Pyrrolidine inhibitors of iap

Info

Publication number
HK1109155A1
HK1109155A1 HK08103339.6A HK08103339A HK1109155A1 HK 1109155 A1 HK1109155 A1 HK 1109155A1 HK 08103339 A HK08103339 A HK 08103339A HK 1109155 A1 HK1109155 A1 HK 1109155A1
Authority
HK
Hong Kong
Prior art keywords
iap
inhibitors
pyrrolidine
pyrrolidine inhibitors
compounds
Prior art date
Application number
HK08103339.6A
Other languages
English (en)
Inventor
Frederick Cohen
John A Flygare
Cuong Ly
Vickie Hsiao-Wei Tsui
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1109155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1109155A1 publication Critical patent/HK1109155A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
HK08103339.6A 2004-12-20 2008-03-26 Pyrrolidine inhibitors of iap HK1109155A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63820204P 2004-12-20 2004-12-20
PCT/US2005/046161 WO2006069063A1 (en) 2004-12-20 2005-12-19 Pyrrolidine inhibitors of iap

Publications (1)

Publication Number Publication Date
HK1109155A1 true HK1109155A1 (en) 2008-05-30

Family

ID=36129810

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103339.6A HK1109155A1 (en) 2004-12-20 2008-03-26 Pyrrolidine inhibitors of iap

Country Status (19)

Country Link
US (4) US20060167066A1 (de)
EP (1) EP1836201B2 (de)
JP (2) JP5007235B2 (de)
KR (2) KR101278732B1 (de)
CN (1) CN101146803A (de)
AT (1) ATE477254T1 (de)
AU (1) AU2005319305B2 (de)
CA (1) CA2588921C (de)
DE (1) DE602005022936D1 (de)
DK (1) DK1836201T4 (de)
EA (1) EA019420B1 (de)
ES (1) ES2349110T5 (de)
HK (1) HK1109155A1 (de)
IL (1) IL183514A (de)
MX (1) MX2007007195A (de)
NO (1) NO339157B1 (de)
NZ (1) NZ589670A (de)
WO (1) WO2006069063A1 (de)
ZA (1) ZA200704910B (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102820A1 (en) 2001-06-20 2002-12-27 Nuevolution A/S Nucleoside derivatives for library preparation
IL163822A0 (en) 2002-03-15 2005-12-18 Nuevolution As An improved method for synthesising templated molecules
US10730906B2 (en) 2002-08-01 2020-08-04 Nuevolutions A/S Multi-step synthesis of templated molecules
PT1558744E (pt) 2002-10-30 2011-09-22 Nuevolution As Codificação enzimática
ATE450609T1 (de) 2002-12-19 2009-12-15 Nuevolution As Durch quasizufallsstrukturen und funktionen geführte synthesemethode
US20070026397A1 (en) 2003-02-21 2007-02-01 Nuevolution A/S Method for producing second-generation library
ATE447626T1 (de) 2003-09-18 2009-11-15 Nuevolution As Methode zur gewinnung struktureller informationen kodierter moleküle und zur selektion von verbindungen
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
CN103083644B (zh) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
EP1883627B1 (de) 2005-05-18 2018-04-18 Pharmascience Inc. An die bir-domäne bindende verbindungen
JP2008545008A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
DE102005046907A1 (de) 2005-09-30 2007-04-12 Voith Patent Gmbh Verfahren und Vorrichtung zur Herstellung einer Tissuebahn
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
DK3305900T3 (da) 2005-12-01 2021-10-25 Nuevolution As Enzymatic encoding methods for efficient synthesis of large libraries
EP1973899A4 (de) * 2005-12-19 2010-10-20 Genentech Inc Hemmer von iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AU2007276760B2 (en) * 2006-07-24 2012-01-19 Tetralogic Pharmaceuticals Corporation Dimeric IAP antagonists
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
BRPI0719221A2 (pt) * 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
MX2009010667A (es) 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
NZ580226A (en) * 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
JP5176452B2 (ja) * 2007-09-27 2013-04-03 住友化学株式会社 光学活性なテトラヒドロピラニルグリシン化合物の製造方法
KR20100110870A (ko) * 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
TW201011006A (en) * 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
CN102124004A (zh) * 2008-08-16 2011-07-13 健泰科生物技术公司 Iap的氮杂吲哚抑制剂
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
MX351274B (es) 2009-08-12 2017-10-06 Novartis Ag Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis.
EP2478358A1 (de) 2009-09-18 2012-07-25 Novartis AG Biomarker für iap-hemmerverbindungen
EP2784076A1 (de) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimere SMAC-Mimetika
AR079528A1 (es) * 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
LT2558577T (lt) 2010-04-16 2019-03-12 Nuevolution A/S Bifunkciniai kompleksai ir tokių kompleksų gamybos ir naudojimo būdai
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112013023798A2 (pt) 2011-03-22 2016-09-20 Syngenta Participations Ag compostos inseticidas
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102757426A (zh) * 2011-04-28 2012-10-31 中国医学科学院医药生物技术研究所 一种苯并异恶唑基取代的噻唑类化合物、制备方法及用途
NO2755614T3 (de) 2012-01-03 2018-03-31
CN117736134A (zh) 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
JP6513019B2 (ja) 2012-05-04 2019-05-15 ノバルティス アーゲー Ｉａｐインヒビター治療のためのバイオマーカー
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9994843B2 (en) * 2013-02-15 2018-06-12 National University Corporation Tokyo Medical And Dental University Method for assaying microRNA, cancer therapeutic agent, and medicinal composition containing same for cancer therapy
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
EP2968590B1 (de) 2013-03-15 2018-09-05 Novartis AG Antikörper-wirkstoff-konjugate
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
CN107428734A (zh) 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3559002A4 (de) 2016-12-23 2021-02-17 Arvinas Operations, Inc. Auf egfr-proteolyse gerichtete chimäre moleküle und zugehörige verfahren zur verwendung
JP2020504741A (ja) 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018140809A1 (en) 2017-01-26 2018-08-02 Arvinas, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630162A1 (de) 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin-gepfropfte proteine und verfahren zur verwendung
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
EP3658235A1 (de) * 2017-07-25 2020-06-03 Hepagene Therapeutics, Inc. Dimere peptidinhibitoren von apoptoseproteinen
EA202091169A1 (ru) * 2017-11-13 2020-08-06 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. Применяемые в качестве ингибиторов iap миметики smac и их применение
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
TWI812673B (zh) 2018-02-12 2023-08-21 美商富曼西公司 用於防治無脊椎害蟲之萘異噁唑啉化合物
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
JOP20210001A1 (ar) 2018-07-10 2021-01-05 Novartis Ag مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
WO2020051564A1 (en) 2018-09-07 2020-03-12 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
JOP20210159A1 (ar) 2018-12-21 2023-01-30 Novartis Ag أجسام مضادة لـ pmel17 ومترافقات منها
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US20220185815A1 (en) 2019-03-06 2022-06-16 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
US20220177453A1 (en) * 2019-05-10 2022-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystallization of smac mimic used as iap inhibitor and preparation method thereof
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
EP4007592A1 (de) 2019-08-02 2022-06-08 LanthioPep B.V. Rezeptoragonisten von angiotensin typ 2 (at2) zur behandlung von krebs
CA3165399A1 (en) 2019-12-20 2021-06-24 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
EP4165169A1 (de) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitoren und deren verwendungen
US20230321067A1 (en) 2020-06-23 2023-10-12 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP2023536164A (ja) 2020-08-03 2023-08-23 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3235132A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
CA2012306A1 (en) 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
JP2000500742A (ja) 1995-10-30 2000-01-25 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害剤
WO1998046597A1 (en) 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
EP1141708A1 (de) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Auf avidität basierte verfahren und zusammensetzungen zur identifizierung von kleinen organischen ligandmolekülen, die biologische zielmoleküle binden
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
DK1373263T3 (da) 2001-04-05 2005-03-07 Torrent Pharmaceuticals Ltd Heterocycliske forbindelser til aldringsrelaterede og diabetesbetingede vaskulære sygdomme
US20050176649A1 (en) 2001-05-31 2005-08-11 Mclendon George Iap binding peptides and assays for identifying compounds that bind iap
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
US20060128632A1 (en) * 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
AU2003290083A1 (en) 2002-08-13 2004-03-11 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin's lymphomas
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
ATE400812T1 (de) 2003-02-07 2008-07-15 Genentech Inc Zusammensetzungen und verfahren für verstärkte apoptose
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
WO2005049853A2 (en) 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2005069888A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
EP1773348A4 (de) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc Tetrapeptid-analoga
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
CN103083644B (zh) 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
EP1883627B1 (de) 2005-05-18 2018-04-18 Pharmascience Inc. An die bir-domäne bindende verbindungen
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (de) 2005-12-19 2010-10-20 Genentech Inc Hemmer von iap
US7205737B1 (en) 2006-01-04 2007-04-17 Robert Bosch Gmbh Systems and methods of monitoring a motor load
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7807699B2 (en) 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
EP2013240B1 (de) 2006-04-07 2017-05-31 Piotrek Co., Ltd. Verfahren zur herstellung von vernetzten nitroxidpolymeren
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI0719221A2 (pt) 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
WO2008079735A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
KR20100110870A (ko) 2008-01-11 2010-10-13 제넨테크, 인크. Ｉａｐ의 억제제
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
CN102124004A (zh) 2008-08-16 2011-07-13 健泰科生物技术公司 Iap的氮杂吲哚抑制剂

Also Published As

Publication number Publication date
EP1836201A1 (de) 2007-09-26
KR101278732B1 (ko) 2013-07-09
AU2005319305B2 (en) 2012-08-23
JP2008524333A (ja) 2008-07-10
US20090176822A1 (en) 2009-07-09
US8609845B2 (en) 2013-12-17
DK1836201T3 (da) 2010-12-06
ES2349110T5 (es) 2013-11-27
US20090318409A1 (en) 2009-12-24
JP5007235B2 (ja) 2012-08-22
CN101146803A (zh) 2008-03-19
ATE477254T1 (de) 2010-08-15
NZ589670A (en) 2013-01-25
KR20070089174A (ko) 2007-08-30
EP1836201B1 (de) 2010-08-11
DE602005022936D1 (de) 2010-09-23
EP1836201B2 (de) 2013-09-04
EA019420B1 (ru) 2014-03-31
MX2007007195A (es) 2007-10-08
ZA200704910B (en) 2008-09-25
ES2349110T3 (es) 2010-12-28
KR20120127754A (ko) 2012-11-23
AU2005319305A1 (en) 2006-06-29
NO20073783L (no) 2007-09-19
EA200701467A1 (ru) 2007-12-28
US9040706B2 (en) 2015-05-26
NO339157B1 (no) 2016-11-14
CA2588921C (en) 2015-10-20
JP2012184230A (ja) 2012-09-27
US20060167066A1 (en) 2006-07-27
DK1836201T4 (da) 2013-11-11
IL183514A (en) 2015-11-30
CA2588921A1 (en) 2006-06-29
WO2006069063A1 (en) 2006-06-29
IL183514A0 (en) 2007-09-20
US20140080805A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
HK1109155A1 (en) Pyrrolidine inhibitors of iap
UA96565C2 (ru) Пиридильные ингибиторы хеджхоговской передачи сигнала
WO2007106192A3 (en) Inhibitors of iap
TW200634018A (en) Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and uses
TW200942533A (en) Pyridyl inhibitors of hedgehog signalling
TW200745028A (en) Novel sulphonylpyrroles
IL177962A0 (en) Compounds and methods for treating dyslipidemia
NO20070606L (no) Inhibitorer av IAP
TW200745027A (en) Novel sulphonylpyrroles
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
TW200640924A (en) VEGF-R2 inhibitors and methods
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
TW200722427A (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
TW200510317A (en) Caspase inhibitors and uses thereof
WO2007120333A3 (en) Tetracyclic kinase inhibitors
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
WO2007053819A3 (en) Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
MX2010007543A (es) Inhibidores de iap.
TW200740781A (en) Novel compounds
ZA200801332B (en) Pentacyclic kinase inhibitors
MX2010010876A (es) Piperidinas sustituidas como compuestos terapeuticos.
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
SI1358182T1 (en) Diazocine derivates and their use as tryptase inhibitors

Legal Events

Date Code Title Description
AM43 Amendment of standard patent following opposition or revocation proceedings in the designated patent office (acc. sect 43 patent ordinance)